Anthropic Partners With Six Drug Developers to Use Claude in Rare Muscle Disease Research
Anthropic is working with six medicine developers, including Bristol Myers Squibb, to apply its Claude AI to finding treatments for a rare childhood muscle-wasting disease. The company has launched Anthropic Drug Discovery programs targeting rare childhood muscular dystrophy. Other named partners include BigHat Biosciences, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. Anthropic says Claude handles much of the scientific and operational work in these internal programs, though it has not disclosed commercial terms or whether any Claude-assisted work has entered formal clinical testing.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in